

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 February 2025 (20.02.2025)



(10) International Publication Number
WO 2025/038421 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/445 (2006.01)

(21) International Application Number:

PCT/US2024/041648

(22) International Filing Date:

09 August 2024 (09.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/532,264 11 August 2023 (11.08.2023) US
63/633,404 12 April 2024 (12.04.2024) US

(71) Applicant: JNANA THERAPEUTICS INC. [US/US];
One Design Center Place, Suite 19-400, Boston, MA 02210
(US).

(72) Inventors: HOLLIBAUGH, Ryan, A.; 120 Holmes St.
#309, Quincy, MA 02171 (US). PARK, Hyejin; 99 Kneec-
land St, #apt 315, Boston, MA 02111 (US).

(74) Agent: GORDON, Dana, M. et al.; Patent Group Fo-
ley Hoag LLP, 155 Seaport Boulevard, Boston, MA
02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: BICYCLIC HETEROARYL-CONTAINING PIPERIDINE INHIBITORS OF SLC6A19 FUNCTION

(57) Abstract: Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport.



WO 2025/038421 A1